PWP
BNTX icon

Perfromance Wealth Partners’s BioNTech BNTX Stock Holding History

Perfromance Wealth Partners’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,000
Closed -$228K – 174
2024
Q4 		$228K Hold
2,000
– – 0.01% 165
2024
Q3 		$238K Buy
+2,000
New +$184K 0.01% 167
2024
Q1 		– Sell
-2,000
Closed -$211K – 167
2023
Q4 		$211K Buy
+2,000
New +$202K 0.01% 152

Other funds holding BNTX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Perfromance Wealth Partners's BNTX Position: Q1 2025 in Review

Perfromance Wealth Partners sold out of BioNTech (BNTX) in Q1 2025, closing a stake of 2,000 shares — an estimated $228K sold.

Perfromance Wealth Partners first reported a position in BNTX in Q4 2023 and held it in 3 quarters. The position peaked at $238K in Q3 2024. 280 funds tracked by Wall St. Rank hold BNTX as of Q1 2025.

  • Perfromance Wealth Partners reported no remaining BioNTech position as of Q1 2025 after selling out during the quarter.
  • Perfromance Wealth Partners sold 2,000 BioNTech shares in Q1 2025, an estimated $228K.
  • Perfromance Wealth Partners first reported a position in BioNTech in Q4 2023 and held it in 3 quarters.
  • Perfromance Wealth Partners's BioNTech position peaked at $238K in Q3 2024.
  • 280 funds tracked by Wall St. Rank held BioNTech as of Q1 2025.

Based on Perfromance Wealth Partners's 13F filing for Q1 2025, filed 22 Apr 2025.